Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

Why is DoorDash acquiring Deliveroo and SevenRooms? How will Trump's tariffs impact toy prices? What caused Newark Airport's recent flight chaos? Why did AMD report strong Q1 revenue growth? How are US-China trade talks evolving this week? What is behind WeightWatchers' recent bankruptcy filing? Why are Tesla’s European sales plummeting? How has Trump's trade policy affected US exports? What are the implications of EU-US tariff tensions?

Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance

benzinga.com/general/biotech/25/05/45208824/vertex-pharmaceuticals-stock-falls-on-q1-earnings-revenue-miss-company-raises-low-end-of-fy25-rev

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reported first-quarter financial results after the market close on Monday. Here’s a look at the key highlights from the period.
Q1 Revenue: $2.77 billion versus estimates of $2.85 billion
Q1 EPS: $4.06, versus estimates of $4.32
Total revenue grew…

This story appeared on benzinga.com, 2025-05-05 21:00:16.